Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tango Therapeutics, Inc. (TNGX : NSDQ)
 
 • Company Description   
Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

Number of Employees: 91

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.41 Daily Weekly Monthly
20 Day Moving Average: 220,928 shares
Shares Outstanding: 87.90 (millions)
Market Capitalization: $475.52 (millions)
Beta: 0.58
52 Week High: $17.97
52 Week Low: $4.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.50% -17.21%
12 Week -40.15% -34.20%
Year To Date -50.55% -39.58%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 BINNEY ST SUITE 700
-
CAMBRIDGE,MA 02142
USA
ph: 857-320-4900
fax: -
None http://www.tangotx.com
 
 • General Corporate Information   
Officers
Barbara Weber - President and Chief Executive Officer; Director
Alexis Borisy - Chairman
Daniella Beckman - Chief Financial Officer
Lesley Ann Calhoun - Director
Aaron Davis - Director

Peer Information
Tango Therapeutics, Inc. (CORR.)
Tango Therapeutics, Inc. (RSPI)
Tango Therapeutics, Inc. (CGXP)
Tango Therapeutics, Inc. (BGEN)
Tango Therapeutics, Inc. (GTBP)
Tango Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87583X109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 87.90
Most Recent Split Date: (:1)
Beta: 0.58
Market Capitalization: $475.52 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.48
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -16.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 0.73%
ROE
03/31/22 - -26.12
12/31/21 - -23.68
09/30/21 - -
ROA
03/31/22 - -16.20
12/31/21 - -12.48
09/30/21 - -
Current Ratio
03/31/22 - 11.75
12/31/21 - 12.10
09/30/21 - 12.30
Quick Ratio
03/31/22 - 11.75
12/31/21 - 12.10
09/30/21 - 12.30
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -389.46
12/31/21 - -156.43
09/30/21 - -
Book Value
03/31/22 - 3.64
12/31/21 - 3.94
09/30/21 - 4.18
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©